Piramal Group to boost financial business

Piramal Healthcare, which specialises in contract manufacturing and over-the-counter drugs, is looking to raise its research and development spend to […]

Business News

Remote patient monitoring market growing The European remote patient monitoring market is growing, but slowly, due to limited government reimbursement, […]

NEWS REVIEW – BUSINESS

[This article was published in the August 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]

Business News

Piramal Healthcare to invest in China

Pirmal Healthcare has said it will invest in manufacturing facilities in China and is looking for acquisitions.

Piramal Diagnostic eyeing acquisitions

Aiming to tap the booming healthcare sector, Piramal Healthcare’s (formerly Nicholas Piramal) diagnostic division, Piramal Diagnostic Services (formerly Wellspring), is in talks with 15 diagnostic centres for acquisition.

Hiranandani hospital outsources radiology services to Wellspring

Leading drugmaker, Nicholas Piramal India has announced that its subsidiary Wellspring is partnering with Dr. L H Hiranandani Hospital. This partnership entails the complete outsourcing of the radiology department at Dr. L H Hiranandani Hospital to Wellspring.

Wockhardt hiving off R&D business

Drug maker Wockhardt has announced it will spin off its R&D business and list the new company on stock exchange on January 1, 2009. The company thus has followed similar moves by other pharma companies, who have hived off their research and development units.

CRAMS to global pharma companies, give good returns

The pharma sector may have underperformed in the Sensex , but companies providing contract research and manufacturing services (CRAMS) to global pharma companies have given good returns.

CRAMS to global pharma companies, give good returns

The pharma sector may have underperformed in the Sensex , but companies providing contract research and manufacturing services (CRAMS) to global pharma companies have given good returns.

NPIL, Merck in research deal for cancer drugs

Nicholas Piramal (NPIL) has reportedly signed a research deal potentially worth a maximum revenue of USD 350 million with US pharmaceutical giant Merck & Co to carry out early discovery and development of two new cancer drugs, the two companies said on Monday.